30-Jan-2026
Download PDF
Glenmark Pharmaceuticals
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Third Quarter and Nine Months ended 31st December 2025.
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
Widely read:
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
